Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism
Felix Jansen1, Xiaoyan Yang2, Katharina Baumann1
1Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University, Bonn, Germany.
Abstract:
Endothelial microparticles (EMP) are released from activated or apoptotic endothelial cells (ECs) and can be taken up by adjacent ECs, but their effect on vascular inflammation after engulfment is largely unknown. We sought to determine the role of EMP in EC inflammation. In vitro, EMP treatment significantly reduced tumour necrosis factor-α-induced endothelial intercellular adhesion molecule (ICAM)-1 expression on mRNA and protein level, whereas there was no effect on vascular cell adhesion molecule-1 expression. Reduced ICAM-1 expression after EMP treatment resulted in diminished monocyte adhesion in vitro. In vivo, systemic treatment of ApoE-/- mice with EMP significantly reduced murine endothelial ICAM-1 expression. To explore the underlying mechanisms, Taqman microRNA array was performed and microRNA (miR)-222 was identified as the strongest regulated miR between EMP and ECs. Following experiments demonstrated that miR-222 was transported into recipient ECs by EMP and functionally regulated expression of its target protein ICAM-1 in vitro and in vivo. After simulating diabetic conditions, EMP derived from glucose-treated ECs contained significantly lower amounts of miR-222 and showed reduced anti-inflammatory capacity in vitro and in vivo. Finally, circulating miR-222 level was diminished in patients with coronary artery disease (CAD) compared to patients without CAD. EMPs promote anti-inflammatory effects in vitro and in vivo by reducing endothelial ICAM-1 expression via the transfer of functional miR-222 into recipient cells. In pathological hyperglycaemic conditions, EMP-mediated miR-222-dependent anti-inflammatory effects are reduced.
Insights
Endothelial microparticles (EMPs) reduce vascular inflammation by transferring miR-222, which lowers ICAM-1 expression. Diabetic conditions impair this anti-inflammatory effect, with lower miR-222 found in coronary artery disease patients.
Area of Science:
- Vascular Biology
- Molecular Medicine
- Immunology
Background:
- Endothelial microparticles (EMPs) are released from endothelial cells (ECs) and their role in vascular inflammation is unclear.
- Understanding EMPs' impact on ECs is crucial for developing treatments for inflammatory vascular diseases.
Purpose of the Study:
- To investigate the role of EMPs in endothelial inflammation.
- To elucidate the mechanisms by which EMPs affect endothelial cells and vascular inflammation.
Main Methods:
- In vitro studies using ECs treated with EMPs and tumor necrosis factor-α.
- In vivo studies using ApoE-/- mice treated with EMPs.
- Taqman microRNA array to identify regulated microRNAs, followed by functional experiments with miR-222.
Main Results:
- EMPs reduced ICAM-1 expression and monocyte adhesion in vitro and in vivo.
- miR-222 was transferred by EMPs to ECs, regulating ICAM-1 expression.
- Diabetic conditions reduced miR-222 in EMPs, diminishing their anti-inflammatory capacity.
- Lower circulating miR-222 levels were observed in patients with coronary artery disease.
Conclusions:
- EMPs exert anti-inflammatory effects by transferring miR-222, reducing endothelial ICAM-1 expression.
- Impaired EMP-mediated anti-inflammatory effects under hyperglycemic conditions may contribute to vascular disease progression.
- Circulating miR-222 levels may serve as a biomarker for coronary artery disease.
Related Concept Videos
MicroRNAs
MicroRNAs
Regulation of Angiogenesis and Blood Supply


